NCAM1 and melanoma: Quantification of CD56/MLANA double-positive melanoma cells, MLANA+ melanoma cells, CD68+ macrophages, and CD8+ T-cells in five regions of interest (ROI) (Fig. 8d, e, Supplementary Data 1) showed that on average 13% of all MLANA+ cells (3,171 cells) were CD56/MLANA double-positive (430 cells).